dr. kahl on adct-402 for relapsed/refractory b-cell non-hodgkin lymphoma
Published 7 years ago • 512 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
2:48
adct-402 - a drug to watch
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
1:31
dr. kahl on efficacy of targeted agents in relapsed/refractory indolent lymphomas
-
5:33
management of refractory follicular lymphoma
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
4:07
author voices: brad kahl, md
-
0:56
dr. kahl on the potential of car t-cell therapy in mcl
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
0:57
dr. kahl discusses unmet needs in mcl
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
0:54
dr. kahl on patient preference in treatment selection for cll
-
1:15
dr. garcia-sanz on combination chemotherapy for relapsed/refractory hodgkin lymphoma
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
2:03
dr. kahl on considerations for treatment strategies in cll
-
1:35
dr. kahl on frontline therapy selection in cll
-
1:02
brad s. kahl, md, considers the unmet medical needs in treatment of hodgkin lymphoma